CoChat
Sign Up
Cited by 177

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Pape, Simon, Snijders, Romée J.A.L.M., Gevers, Tom J.G., Chazouilleres, Oliver, Dalekos, George N., Hirschfield, Gideon M., Lenzi, Marco, Trauner, Michael, Manns, Michael P., Vierling, John M., Montano-Loza, Aldo J., Lohse, Ansgar W., Schramm, Christoph, Drenth, Joost P.H., Heneghan, Michael A., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Drenth, J., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Ines Lopez, S., de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M.·2022·Journal of Hepatology
DOI 10.1016/j.jhep.2021.12.041
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.12.041

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. Mack, 2019, Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases, Hepatology
  2. Galaski, 2021, Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing, J Hepatol, 74, 312, 10.1016/j.jhep.2020.07.032 · DOI
  3. Mieli-Vergani, 2018, Autoimmune hepatitis, Nat Rev Dis primers, 4, 18017, 10.1038/nrdp.2018.17 · DOI
  4. Herkel, 2020, Autoimmune hepatitis: possible triggers, potential treatments, J Hepatol, 73, 446, 10.1016/j.jhep.2020.03.015 · DOI
  5. Weiler-Normann, 2021, Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation, Curr Opin Gastroenterol, 37, 86, 10.1097/MOG.0000000000000701 · DOI
  6. Doycheva, 2019, Autoimmune hepatitis: current and future therapeutic options, Liver Int, 39, 1002, 10.1111/liv.14062 · DOI
  7. Johnson, 1993, Meeting report: international autoimmune hepatitis group, Hepatology, 18, 998, 10.1002/hep.1840180435 · DOI
  8. Manns, 2010, Diagnosis and management of autoimmune hepatitis, Hepatology, 51, 2193, 10.1002/hep.23584 · DOI · Paper page
  9. Manns, 2015, Autoimmune hepatitis--Update 2015, J Hepatol, 62, S100, 10.1016/j.jhep.2015.03.005 · DOI
  10. van Buuren, 2015, Surrogate endpoints for optimal therapeutic response to UDCA in primary biliary cholangitis, Dig Dis, 33, 118, 10.1159/000440759 · DOI
  11. Ponsioen, 2018, Design and endpoints for clinical trials in primary sclerosing cholangitis, Hepatology, 68, 1174, 10.1002/hep.29882 · DOI
  12. Ponsioen, 2016, Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process, Hepatology, 63, 1357, 10.1002/hep.28256 · DOI
  13. Cook, 1971, Controlled prospective trial of corticosteroid therapy in active chronic hepatitis, Q J Med, 40, 159
  14. Murray-Lyon, 1973, Controlled trial of prednisone and azathioprine in active chronic hepatitis, Lancet (London, England), 1, 735, 10.1016/S0140-6736(73)92125-9 · DOI
  15. Summerskill, 1975, Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared, Gut, 16, 876, 10.1136/gut.16.11.876 · DOI
  16. Tage-Jensen, 1982, Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification, Liver, 2, 95, 10.1111/j.1600-0676.1982.tb00184.x · DOI
  17. Czaja, 1999, Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial, Hepatology (Baltimore, Md), 30, 1381, 10.1002/hep.510300603 · DOI
  18. Stellon, 1985, Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis, Lancet (London, England), 1, 668, 10.1016/S0140-6736(85)91329-7 · DOI
  19. Stellon, 1988, Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal, Hepatology (Baltimore, Md), 8, 781, 10.1002/hep.1840080414 · DOI
  20. Manns, 2010, Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis, Gastroenterology, 139, 1198, 10.1053/j.gastro.2010.06.046 · DOI
  21. Czaja, 1993, Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses, J Hepatol, 17, 180, 10.1016/S0168-8278(05)80035-2 · DOI
  22. Stern, 1977, Controlled trial of synthetic D-penicillamine and prednisone in maintenance therapy for active chronic hepatitis, Gut, 18, 19, 10.1136/gut.18.1.19 · DOI
  23. Hegarty, 1984, Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis, Gut, 25, 279, 10.1136/gut.25.3.279 · DOI
  24. Bittencourt, 2015, Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver, Arquivos de gastroenterologia, 52, 15, 10.1590/s0004-28032015000500002 · DOI
  25. 2017, Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015), J Dig Dis, 18, 247
  26. Maverakis, 2014, International consensus criteria for the diagnosis of Raynaud's phenomenon, J Autoimmun, 48–49, 60, 10.1016/j.jaut.2014.01.020 · DOI
  27. Lantinga, 2016, International multi-specialty Delphi survey: identification of diagnostic criteria for hepatic and renal cyst infection, Nephron, 134, 205, 10.1159/000446664 · DOI
  28. Pape, 2019, Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months, Clin Gastroenterol Hepatol
  29. Hartl, 2016, Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis, J Hepatol, 65, 769, 10.1016/j.jhep.2016.05.023 · DOI
  30. Desmet, 1994, Classification of chronic hepatitis: diagnosis, grading and staging, Hepatology (Baltimore, Md), 19, 1513, 10.1002/hep.1840190629 · DOI
  31. Ishak, 1995, Histological grading and staging of chronic hepatitis, J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 · DOI
  32. Gleeson, 2011, British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis, Gut, 60, 1611, 10.1136/gut.2010.235259 · DOI
  33. 2015, EASL clinical practice guidelines: autoimmune hepatitis, J Hepatol, 63, 971, 10.1016/j.jhep.2015.06.030 · DOI · Paper page
  34. Zachou, 2011, Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients, J Hepatol, 55, 636, 10.1016/j.jhep.2010.12.032 · DOI
  35. Choi, 2019, Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country, Liver Int, 39, 985, 10.1111/liv.14082 · DOI
  36. Biewenga, 2021, Aminotransferases during treatment in AIH aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: a landmark analysis, Clin Gastroenterol Hepatol
  37. Zachou, 2016, A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis, Aliment Pharmacol Ther, 43, 1035, 10.1111/apt.13584 · DOI
  38. Pape, 2019, Clinical management of autoimmune hepatitis, United Eur Gastroenterol J, 7, 1156, 10.1177/2050640619872408 · DOI
  39. Al-Chalabi, 2007, Remission in autoimmune hepatitis: what is it, and can it ever be achieved?, Am J Gastroenterol, 102, 1013, 10.1111/j.1572-0241.2007.01147.x · DOI
  40. Lohse, 2020, Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference Network on hepatological diseases and the international autoimmune hepatitis group, J Hepatol, 73, 1496, 10.1016/j.jhep.2020.07.023 · DOI
  41. Laschtowitz, 2021, Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis, JHEP Rep, 3, 100321, 10.1016/j.jhepr.2021.100321 · DOI
  42. Hartl, 2018, Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis, J Hepatol, 68, 754, 10.1016/j.jhep.2017.11.020 · DOI
  43. Xu, 2017, Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis, J Gastroen Hepatol, 32, 639, 10.1111/jgh.13508 · DOI
  44. Zachou, 2021, FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases, Ann Hepatol, 22, 100285, 10.1016/j.aohep.2020.10.013 · DOI
  45. Soloway, 1972, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis, Gastroenterology, 63, 820, 10.1016/S0016-5085(19)33223-8 · DOI
  46. Janik, 2019, Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: a prospective, single-centre study, Liver Int, 39, 215, 10.1111/liv.13960 · DOI

Cited by

Sorted by citations

Metadata

Authors
Pape, S., Snijders, R. J. A. L. M., Gevers, T. J. G., Chazouilleres, O., Dalekos, G. N., Hirschfield, G. M., Lenzi, M., Trauner, M., Manns, M. P., Vierling, J. M., Montano-Loza, A. J., Lohse, A. W., Schramm, C., Drenth, J. P. H., Heneghan, M. A., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Drenth, J., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Ines Lopez, S., de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., & Zeniya, M.
ORCID
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-04
Volume
76
Issue
4
Pages
841-849
ISSN
0168-8278
DOI
10.1016/j.jhep.2021.12.041
Cited by
177
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review